Alivus Life Sciences reported record revenues of ₹6,729 Mn and its highest-ever EBITDA margin of 36.4%. Revenue grew by 14.4% QoQ and 4.8% YoY. For the nine months ended December 31, 2025, revenue from operations was ₹18,627 Mn, a growth of 7.2% YoY. The company also generated free cash flow of ₹2,207 Mn during the period.
Strong Financial Performance
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its financial results for Q3 FY26, highlighting a significant upturn in its performance. The company reported record revenues from operations of ₹6,729 Mn, marking a growth of 14.4% compared to the previous quarter and 4.8% year-over-year.
EBITDA and Margins
The company’s EBITDA for Q3 FY26 stood at ₹2,452 Mn, reflecting substantial growth of 26.5% QoQ and 22.1% YoY. The EBITDA margin reached a record high of 36.4%, representing an increase of 340 bps QoQ and 510 bps YoY. For the nine months ended December 31, 2025, EBITDA was ₹6,204 Mn, up 22.0% YoY, with EBITDA margins at 33.3%.
Profitability
The Profit After Tax (PAT) for Q3 FY26 was reported at ₹1,503 Mn, showing growth of 15.5% QoQ and 9.7% YoY. PAT margins were at 22.3%. For the nine-month period, PAT stood at ₹4,019 Mn, a growth of 16.9% YoY, with PAT margins at 21.6%.
Cash Flow and Debt Position
During the nine months ended December 31, 2025, the company generated a strong free cash flow of ₹2,207 Mn, leading to total Cash and Cash Equivalents (including short term investments) of ₹7,330 Mn. Alivus Life Sciences continues to operate as a net debt-free company.
Management Commentary
Dr. Yasir Rawjee, MD & CEO of Alivus Life Sciences Limited, noted a clear improvement in operating performance, with the CDMO business recovering as expected. He also highlighted robust growth in Non-GPL business, especially across key markets including Europe, Japan, LATAM, ROW, and India, which grew by 16% YoY during 9MFY26. The company expects Non-GPL to sustain its growth momentum, reinforcing confidence in delivering high single-digit revenue growth for FY26 and sustaining margin expansion.
Strategic Initiatives
Alivus Life Sciences has acquired land in Taloja (Navi Mumbai) to establish a state-of-the-art R&D center, designed to advance complex chemistry and oncology research. This center will focus on flow chemistry, complex products, particle engineering, and green chemistry.
Source: BSE
